India’s SME stock platforms, designed as a launchpad to the mainboard, are seeing a significant slowdown in company migrations. Stricter listing norms and increased tenure requirements implemented by exchanges have effectively filtered out smaller players, leading to a sharp decline in the number of companies successfully transitioning to the mainboard in recent years.
Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, Biocon
Biocon CEO Siddharth Mittal outlines the company’s strategy in the competitive GLP-1 market. Focusing on liraglutide’s launch in the US and Europe, he highlights opportunities